244 related articles for article (PubMed ID: 28323948)
1. Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women.
Ng J; Chwalisz K; Carter DC; Klein CE
J Clin Endocrinol Metab; 2017 May; 102(5):1683-1691. PubMed ID: 28323948
[TBL] [Abstract][Full Text] [Related]
2. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
Struthers RS; Nicholls AJ; Grundy J; Chen T; Jimenez R; Yen SS; Bozigian HP
J Clin Endocrinol Metab; 2009 Feb; 94(2):545-51. PubMed ID: 19033369
[TBL] [Abstract][Full Text] [Related]
3. Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women.
Archer DF; Ng J; Chwalisz K; Chiu YL; Feinberg EC; Miller CE; Feldman RA; Klein CE
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31650182
[TBL] [Abstract][Full Text] [Related]
4. First-in-Human, Double-Blind, Randomized Controlled Trial of an Oral Dose of GnRH Antagonist TU2670 in Healthy Women.
Han S; Cho YS; Yoon SK; Lim KS; Cho SH; Kim J; Choe S; Jung J; Ghim JL; Choi S; Lee M; Kim SM; Kim HT; Lim HS; Yoon Shim J; Bae KS
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1111-e1120. PubMed ID: 33347565
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
[TBL] [Abstract][Full Text] [Related]
6. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
Archer DF; Stewart EA; Jain RI; Feldman RA; Lukes AS; North JD; Soliman AM; Gao J; Ng JW; Chwalisz K
Fertil Steril; 2017 Jul; 108(1):152-160.e4. PubMed ID: 28579415
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women.
Nagaraja NV; Pechstein B; Erb K; Klipping C; Hermann R; Niebch G; Derendorf H
Clin Pharmacol Ther; 2000 Dec; 68(6):617-25. PubMed ID: 11180022
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women.
Erb K; Klipping C; Duijkers I; Pechstein B; Schueler A; Hermann R
Fertil Steril; 2001 Feb; 75(2):316-23. PubMed ID: 11172833
[TBL] [Abstract][Full Text] [Related]
9. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
[TBL] [Abstract][Full Text] [Related]
10. The effects of estrogen and progesterone on the functional capacity of the gonadotrophs.
Lasley BL; Wang CF; Yen SS
J Clin Endocrinol Metab; 1975 Nov; 41(5):820-6. PubMed ID: 1102551
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women.
Feldman RA; Chiu YL; Klein CE; Ng J
Clin Pharmacokinet; 2021 Aug; 60(8):1003-1013. PubMed ID: 33748934
[TBL] [Abstract][Full Text] [Related]
12. Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature.
Alessandro P; Luigi N; Felice S; Maria PA; Benedetto MG; Stefano A
Arch Gynecol Obstet; 2017 Apr; 295(4):827-832. PubMed ID: 28255765
[TBL] [Abstract][Full Text] [Related]
13. The NK3 Receptor Antagonist ESN364 Suppresses Sex Hormones in Men and Women.
Fraser GL; Ramael S; Hoveyda HR; Gheyle L; Combalbert J
J Clin Endocrinol Metab; 2016 Feb; 101(2):417-26. PubMed ID: 26653113
[TBL] [Abstract][Full Text] [Related]
14. Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment.
Ng J; Duan WR; Marbury T; Schmidt JM; Klein CE
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1053-1061. PubMed ID: 30570832
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women.
Nagaraja NV; Pechstein B; Erb K; Klipping C; Hermann R; Locher M; Derendorf H
J Clin Pharmacol; 2003 Mar; 43(3):243-51. PubMed ID: 12638392
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.
Polepally AR; Ng JW; Salem AH; Dufek MB; Parikh A; Carter DC; Kamradt K; Mostafa NM; Shebley M
J Clin Pharmacol; 2020 Dec; 60(12):1606-1616. PubMed ID: 33045114
[TBL] [Abstract][Full Text] [Related]
17. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
Schlaff WD; Ackerman RT; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Feinberg EC; Hurtado SM; Kim J; Liu R; Mabey RG; Owens CD; Poindexter A; Puscheck EE; Rodriguez-Ginorio H; Simon JA; Soliman AM; Stewart EA; Watts NB; Muneyyirci-Delale O
N Engl J Med; 2020 Jan; 382(4):328-340. PubMed ID: 31971678
[TBL] [Abstract][Full Text] [Related]
18. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers.
Oberyé JJ; Mannaerts BM; Huisman JA; Timmer CJ
Fertil Steril; 1999 Dec; 72(6):1006-12. PubMed ID: 10593372
[TBL] [Abstract][Full Text] [Related]
20. Does timing matter when initiating elagolix in a natural menstrual cycle?
Danis RB; Sriprasert I; Stanczyk FZ; Paulson RJ; Winer SA; Ho JR
F S Rep; 2021 Sep; 2(3):308-313. PubMed ID: 34553156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
